There are 224 different pipeline products in clinical development for hematological malignancies. Twenty-three (10%) of these drugs are in late-phase studies and are forecast to achieve peak sales of $3.5 billion in 2018. Drug developers are keen to replicate the success of the two blockbusters: Biogen Idec/Genentech/Roche's Rituxan (rituximab) and Novartis's Gleevec (imatinib).
Scope
Epidemiology of the hematological malignancies split by disease subtype, covering the seven major markets as well as the top 5 rest of world markets
Overview of the current treatment options for leukemia, lymphoma, multiple myeloma and myelodysplastic syndromes with identification of unmet needs
Examination of the late-phase hematological malignancies pipeline, key company market strategies and opportunities for drug developers
Pipeline insight based on qualitative interviews with key opinion leaders in the field of hematological malignancies
Highlights
There are 13 molecular-targeted therapies, six immunotherapeutic agents and four cytotoxic agents in late-phase clinical development for hematological malignancies. Immunotherapeutic agents are forecast to achieve the highest class sales of $1.7 billion in the seven major markets by 2018.
Pipeline agents holding the greatest commercial potential include the immunoconjugated monoclonal antibodies Arzerra (ofatumumab; Genmab/GlaxoSmithKline), galiximab (Biogen Idec) and lumiliximab (Biogen Idec), as well as the cytotoxic agent pixantrone (Novartis).
Smaller, niche indications are increasingly attracting R&D interest as a result of the high unmet needs that persist in a number of hematological malignancy subtypes. At least 9 (39%) of the 23 late-phase pipeline agents are targeting patient sub-populations to potentially fill gaps in the market and facilitate launch.
Reasons to Purchase
Acquire a detailed appreciation and impartial perspective of the entire hematological malignancies developmental pipeline
Identify the key products in late-phase development based on sales forecasts to 2018 and Datamonitor's drug assessment methodology
Assess how the future treatment of many hematological malignancies will incorporate pipeline products
(0 items)
